Drugs / AXS-05
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04608396 | Aug 2020 → Jul 2021 | major depressive disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03226522 | Jul 2017 → Apr 2020 | Alzheimer disease | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06736509 | Nov 2024 → Feb 2025 | Alzheimer disease | Axsome Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT05557409 | Sep 2022 → Nov 2024 | Alzheimer disease | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04797715 | Dec 2020 → Nov 2022 | Alzheimer disease | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02741791 | Mar 2016 → Mar 2020 | major depressive disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06223880 | Dec 2023 → Mar 2026 overdue | major depressive disorder | Axsome Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AXS-05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06736509 ↗ |
| Known as | dextromethorphan-bupropion | “Experimental: AXS-05 (dextromethorphan-bupropion) up to 25 weeks” NCT06736509 ↗ |
| Route | Oral | “AXS-05 Administered Orally” NCT02741791 ↗ |